Skip to main content
. 2016 Jun 30;6:29131. doi: 10.1038/srep29131

Figure 3. Humoral responses and CMI are increased after 5 doses of Tat DNA vaccine.

Figure 3

Animals were vaccinated ID with 5 doses of 50 μg of pVAX-sTat or pVAX-sTat-IMX313 at 2 week intervals. Splenocytes were collected 14 days after the last dose. Blood and CVLs were collected one day before each vaccination and on the day of euthanasia. (A) ELISA results showing serum anti-Tat IgG titres. (B) Serum neutralisation of Tat transactivation activity, (C) Percentage decline in luminescence (an indicator of the neutralisation of Tat transactivation activity) that is depicted in (B,D) ELISA results showing anti-Tat sIgA titres in CVLs from pVAX-sTat or pVAX-sTat-IMX313 vaccinated mice. Data are representative of 2 independent experiments. (E) Percentage of vaccinated animals in which sIgA was detected after 3–5 vaccine doses in the experiment shown in 3D. (F) IFN-γ ELIspot assay to examine Tat-specific CMI responses following administration of 5 doses of pVAX-sTat or pVAX-sTat-IMX313. Data shown in the entire figure depict the mean (n = 7) ± SEM; an unpaired non-parametric Mann–Whitney U test was used to analyse the statistical significance of the data; *p < 0.05, **p ≤ 0.01, ***p ≤ 0.001 and p ≥ 0.005 = non-significant (ns).